Technical Analysis for ADVM - Adverum Biotechnologies, Inc.

Grade Last Price % Change Price Change
grade D 18.2 3.17% 0.56
ADVM closed up 3.17 percent on Wednesday, August 5, 2020, on 42 percent of normal volume.
Earnings due: Aug 6
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical ADVM trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
20 DMA Resistance Bearish 3.17%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.17%
Inside Day Range Contraction 3.17%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.79%
MACD Bullish Signal Line Cross Bullish 1.79%
Pocket Pivot Bullish Swing Setup 1.79%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Disease Gene Therapy Macular Degeneration Wet Age Related Macular Degeneration Adverum Biotechnologies Gene Therapy Of The Human Retina Gene Therapy Products Rare Genetic Disease Retinoschisis

Is ADVM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 26.98
52 Week Low 4.96
Average Volume 1,117,756
200-Day Moving Average 13.91
50-Day Moving Average 20.45
20-Day Moving Average 17.85
10-Day Moving Average 17.38
Average True Range 1.21
ADX 23.15
+DI 17.19
-DI 19.92
Chandelier Exit (Long, 3 ATRs ) 18.30
Chandelier Exit (Short, 3 ATRs ) 20.15
Upper Bollinger Band 19.94
Lower Bollinger Band 15.75
Percent B (%b) 0.58
BandWidth 23.47
MACD Line -0.77
MACD Signal Line -0.94
MACD Histogram 0.1689
Fundamentals Value
Market Cap 787.83 Million
Num Shares 43.3 Million
EPS -1.52
Price-to-Earnings (P/E) Ratio -11.97
Price-to-Sales 75.42
Price-to-Book 0.71
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.34
Resistance 3 (R3) 19.27 18.82 19.15
Resistance 2 (R2) 18.82 18.53 18.86 19.09
Resistance 1 (R1) 18.51 18.35 18.67 18.58 19.02
Pivot Point 18.06 18.06 18.14 18.10 18.06
Support 1 (S1) 17.75 17.77 17.91 17.82 17.38
Support 2 (S2) 17.30 17.59 17.34 17.31
Support 3 (S3) 16.99 17.30 17.25
Support 4 (S4) 17.06